Navigation Links
Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
Date:2/1/2013

40 bps 

Consumer Healthcare segment net sales increased 14% to $539 million, driven by an increase in sales of existing products of $38 million (contract,  analgesics and smoking cessation categories), $34 million attributable to the Sergeant's and CanAm acquisitions, and new product sales of $12 million (cough/cold, dermatologic and gastrointestinal categories). These combined increases were partially offset by a decline of $13 million in sales of existing products (allergy products and gastrointestinal category) and approximately $5 million in discontinued products.

Adjusted gross and operating margins expanded 30 and 40 basis points, respectively, due to new products and increased manufacturing efficiencies. The disparity between the reported and adjusted margins was due primarily to a charge of approximately $8 million to cost of sales as a result of the step-up of inventory acquired and sold related to the Sergeant's acquisition.

 

Nutritionals

 Nutritionals Segment (in thousands)(see the attached Table II for reconciliation to GAAP numbers)Fiscal 2013

Fiscal 2012Second

Quarter

Ended

Second

Quarter

Ended

 

 

YoY12/29/2012

12/31/2011

% ChangeNet Sales

$121,938

$128,147

-4.8%Reported Gross Profit

$30,145

$28,230

+6.8%Adjusted Gross Profit

$33,194

$31,252

+6.2%Reported Operating Income

$7,160

$4,552

+57.3%Adjusted Operating Income

$14,470

$11,189

+29.3%Reported Gross Margin

24.7%

22.0%

+270 bpsAdjusted Gross Margin

27.2%

24.4%

+280 bpsReported Operating Margin

5.9%

3.6%

+230 bpsAdjusted Operating Margin

11.9%

8.7%

+320 bps 

The Nutritionals segment repo
'/>"/>

SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
2. Perrigo Commences Launch Of Clobetasol Emulsion Propionate Foam, 0.05%
3. Perrigo Company To Release Second Quarter Fiscal Year 2013 Results On February 1, 2013
4. Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
5. Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%
6. Perrigo Company To Present At The Credit Suisse Healthcare Conference
7. Perrigo Reports Record First Quarter Revenue And Adjusted Earnings And Raises Full Year Adjusted EPS Guidance
8. Perrigo Company Announces Appointment Of New Board Of Directors Member
9. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
10. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
11. Perrigo Company Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
(Date:6/19/2013)... 19, 2013 Amber Roberson with ... Benefits, LLC, Native Care Health, LLC and Medcase, ... Health Underwriters’ (NAHU) new professional development course on ... This continuing education course for agents has been ... receive eleven education credits from the Missouri Department ...
(Date:6/19/2013)... The Journal of Parasitology – Although ... software, it creates questions of ethics. For scientific publications, ... already published case shows, scientific publications need clear guidelines ... Journal of Parasitology features a commentary on ... article published in the Journal of the New York ...
(Date:6/19/2013)... study published in the June 19 online edition of ... by researchers from the University of California, San Diego ... that take place when cardiac regeneration occurs in zebrafish ... that various cell lines in the heart are more ... than previously thought. , More importantly, the research reveals ...
(Date:6/19/2013)... reveals significant disparities between minority and white clients ... programs. Moreover, these disparities vary widely from state ... for most states there,s something amiss," says Stephan ... "There are strong racial and ethnic disparities for ... treatment programs successfully, and those disparities are something ...
(Date:6/19/2013)... -- Nearly 70 percent of Americans are ... than half take two, Mayo Clinic researchers say. ... prescribed, their study found. Twenty percent of patients ... to the findings, published online in the journal ... For audio and video of Dr. Jennifer St. ...
Breaking Medicine News(10 mins):Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2
... ... the most widely used resource for consumers looking for a top doctor in their community. ... New York, NY (PRWEB) November 16, 2009 ... many dating sites and search through endless profiles until they find their match. Want to ...
... ... of Trendy Socks for Kids who Wear Ankle-Foot Orthoses (AFOs) , ... Westchester, NY (PRWEB) November 16, 2009 -- Ross ... today its marketplace debut and the launch of “Cool Clothes for Toes,” the first creatively ...
... ... has been selected by Goldline Research as one of the leading Laser ... Laser Eye Surgeons of the United States has been published in the ... vision trials, and originator of LASIK in Denver, Colorado, Dr. Jon Dishler ...
... Nov. 16 Acknowledging that their results are "not ... International Journal of Andrology nevertheless attempt to link reduced masculine ... exposure to phthalates. The researchers, led by Dr. Shanna ... much publicized, study of phthalate exposure to evaluate the play ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 15 ... the Company will hold a teleconference and webcast at 8:00 a.m. ... pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial ... , Conference Call and Webcast Information , To ...
... 15 The World Champion New York Yankees ... at New York Blood Center,s (NYBC) Biennial Chairman,s Dinner this ... The event is chaired by William J. Mullaney, MetLife ... the opportunity to honor these two outstanding supporting organizations as ...
Cached Medicine News:Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 3Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 2Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 3Health News:Swan Study Authors Note Results 'Not Straightforward' 2Health News:Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer 2Health News:World Champion New York Yankees, BNY Mellon to be Honored as New York Blood Center 'Champions of Life' 2
Made exclusively from LactoSorb® Resorbable Copolymer....
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
... Stryker Conquest Suture Retrievers ... that pierce through soft ... through the tissue to ... Conquest Retrievers are front ...
... excising soft tissue more efficiently than a punch ... edge on the straight scissor helps to maintain ... jaws for more efficient resection.,The curved scissors, available ... perfect tools for ACL stump removal, meniscectomies and ...
Medicine Products: